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Abstract
Background: Current guidelines recommend primary percutaneous coronary intervention (PCI) for ST-
segment elevation myocardial infarction (STEMI) as long as it can be performed quickly by an experienced
provider. Unfortunately as time from the onset of symptoms increases, so does the incidence of adverse
cardiac events. For patients in rural areas who face inevitable delays due to long-distance transfers, primary
PCI is a less than perfect option. Other options include full-dose fibrinolytic therapy with routine transfer to a
PCI capable hospital and a relatively new reperfusion strategy called pharmaco-invasive PCI. With multiple
treatment options available, what is the most appropriate management of rural patients with STEMIs when
delays are expected due to long-distance transfers?
Methods: An exhaustive search of available medical literature was conducted using Medline-OVID,
CINAHL, and Web of Science using the keywords: myocardial infarction, fibrinolytic agents, myocardial
reperfusion, and patient transfer. Articles evaluating the efficacy and safety of treatment options for STEMI
patients in rural locations were included. Relevant articles were assessed for quality using GRADE.
Results: Two studies met inclusion criteria and were included in this systematic review. A retrospective
observational study with 259 rural STEMI patients found that in-hospital mortality was higher in patients
with primary PCI (9.3%) compared with fibrinolysis patients (1.9%; P=0.03). A prospective observational
study with 2634 patients found that there was no significant difference in 30-day mortality (5.5 vs 5.6%; P=
0.94), stroke (1.1 vs 1.3%; P= 0.66) or major bleeding (1.5 vs 1.8%; P= 0.65), or re-infarction/ischemia (1.2
vs 2.5%; P= 0.088) in rural patients receiving a pharmaco-invasive therapy compared with patients presenting
directly to the PCI center.
Conclusion: In rural patients with STEMIs, as delays in transfer time increase due to long-distance travel, the
use of fibrinolytic or pharmaco-invasive therapy may be more effective and beneficial than primary PCI
reperfusion therapy.
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Abstract   
 
Background: Current guidelines recommend primary percutaneous coronary 
intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) as long as it 
can be performed quickly by an experienced provider. Unfortunately as time from the 
onset of symptoms increases, so does the incidence of adverse cardiac events. For 
patients in rural areas who face inevitable delays due to long-distance transfers, primary 
PCI is a less than perfect option. Other options include full-dose fibrinolytic therapy with 
routine transfer to a PCI capable hospital and a relatively new reperfusion strategy called 
pharmaco-invasive PCI. With multiple treatment options available, what is the most 
appropriate management of rural patients with STEMIs when delays are expected due to 
long-distance transfers? 
 
Methods:  An exhaustive search of available medical literature was conducted using 
Medline-OVID, CINAHL, and Web of Science using the keywords: myocardial 
infarction, fibrinolytic agents, myocardial reperfusion, and patient transfer. Articles 
evaluating the efficacy and safety of treatment options for STEMI patients in rural 
locations were included. Relevant articles were assessed for quality using GRADE. 
 
Results:  Two studies met inclusion criteria and were included in this systematic review. 
A retrospective observational study with 259 rural STEMI patients found that in-hospital 
mortality was higher in patients with primary PCI (9.3%) compared with fibrinolysis 
patients (1.9%; P=0.03). A prospective observational study with 2634 patients found that 
there was no significant difference in 30-day mortality (5.5 vs 5.6%; P= 0.94), stroke (1.1 
vs 1.3%; P= 0.66) or major bleeding (1.5 vs 1.8%; P= 0.65), or re-infarction/ischemia 
(1.2 vs 2.5%; P= 0.088) in rural patients receiving a pharmaco-invasive therapy 
compared with patients presenting directly to the PCI center.  
 
Conclusion:  In rural patients with STEMIs, as delays in transfer time increase due to 
long-distance travel, the use of fibrinolytic or pharmaco-invasive therapy may be more 
effective and beneficial than primary PCI reperfusion therapy.  
 
Keywords:  Myocardial infarction, myocardial reperfusion, fibrinolytic agents, transfer 
time, rural healthcare  
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The Appropriate Management of Rural Patients with ST-Segment Elevation Myocardial Infarction When Delays are Expected Due to Long-Distance Transfers 
BACKGROUND 
 Almost 1 million acute myocardial infarctions (AMI) occur in the United States 
annually.1 The gold standard of treatment for patients that are diagnosed with a ST-
segment elevation myocardial infarction (STEMI) is primary percutaneous coronary 
intervention (PCI) as long as it can be performed quickly by an experienced provider.2,3 
Rapid initiation of reperfusion with primary PCI for patients with a STEMI limits the 
infarct size and improves the survival rates.4 Unfortunately, for patients requiring primary 
PCI, as time from the onset of symptoms increases, so does the incidence of death, re-
infarction, and stroke.5 The American College of Cardiology and American Heart 
Association guidelines4 currently recommend that primary PCI be performed within 90 
minutes from the patient presentation to the emergency room. However, only 25% of 
hospitals in the United States have the capability to perform primary PCI, and most of 
these are located in urban settings,6 making primary PCI a less than perfect option for 
rural patients with long-distance transfer times.  
Other treatment options include full-dose fibrinolytic therapy with routine transfer 
to a PCI capable hospital for ischemia-guided rescue PCI. Concerns over the safety and 
efficacy of this treatment when compared to primary PCI have overall made it a second-
line reperfusion strategy for the average STEMI patient.7 However, fibrinolytic therapy 
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might allow for the advantage of early reperfusion over primary PCI in rural patients that 
are facing long transfer times.8 Recently, a hybrid method called pharmaco-invasive PCI 
that aims to combine the benefits of both strategies (fibrinolytic therapy followed by 
transfer for early PCI) has shown promise as a new management strategy.9 With multiple 
treatment options available, what is the most appropriate management of rural patients 
with STEMI when delays are expected due to long-distance transfers? 
METHODS 
An exhaustive literature search of available medical literature was conducted 
using Medline-OVID, CINAHL, and Web of Science using the following search terms: 
myocardial infarction, fibrinolytic agents, myocardial reperfusion, and patient transfer. 
Articles with primary data evaluating the efficacy and safety of treatment options for 
STEMI patients in rural locations were included. Relevant articles were assessed for 
quality using the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE).10  
RESULTS 
The initial search of medical literature generated 40 articles for review. Further 
evaluation of relevant data from the generated search yielded a total of two articles that 
met inclusion criteria. Both of these articles were observational studies analyzing the 
treatment of rural patients diagnosed with STEMI. One evaluated the use of fibrinlyitcs,8 
while the other the use of a pharmaco-invasive reperfusion strategy.9 These studies are 
summarized in Table I and their findings are summarized in Tables II and III. 
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Beri et al  
This retrospective observational study8 assessed whether or not the administration 
of fibrinolytics in rural STEMI patients prior to a long-distance hospital transfer resulted 
in transfer delays or worse outcomes when compared with direct transfers for primary 
PCI.  Data was collected using information from the National Registry of Myocardial 
Infarction 5 as well as the Acute Coronary Treatment and Intervention Outcomes 
Network. All patients included in this study were transferred from 14 non-PCI capable 
referral hospitals to Pitt County Memorial Hospital (PCMH), a 24 hour PCI-capable 
hospital in eastern North Carolina. The median distance from the non-PCI hospital to the 
PCI-capable center was 52 miles (interquartile range [IQR], 38-69), with an average 
travel time of 72 minutes (IQR, 50-86) by ground.8  
Patients with STEMI or new left bundle branch block within 12 hours of 
symptom onset were included in the study. The administration of intravenous 
fibrinolytics to STEMI patients was left to the discretion of the admitting ED physician. 
Standard protocols for administration of fibrinolytics, as well as contraindications were 
applied, including uncontrolled hypertension, malignant disease, recent major surgery or 
bleeding, prolonged cardiopulmonary resuscitation, and severe heart failure. Patients that 
qualified for fibrinolysis were given either full-dose tenecteplase (64.4%) or reteplase 
(35.6%) and were eligible for transfer immediately after completion of ﬁbrinolysis. 
Patients who did not meet criteria for fibrinolysis, or had transfer times less than 30 
minutes, were referred for primary PCI.8  
 The authors reviewed 259 patients presenting with a STEMI diagnosis to 
participating non-PCI capable hospitals and were then transferred to PCMH between 
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December 2006 and June 2008. Of these patients, 43 (16.6%) were transferred for 
primary PCI, while the remaining 216 (83.4%) were transferred after administration of 
fibrinolysis for further management. The mean age of patients transferred for primary 
PCI was 65.2 ± 13.5 years, while the mean age for patients transferred after ﬁbrinolysis 
was 58.7 ± 12.5 years. There was a higher rate of congestive heart failure in the primary 
PCI group (20.9%) as compared to the fibrinolytic group (3.7%; P < 0.001). Cardiogenic 
shock was also higher in the primary PCI group (14.0% vs 0.5%; P < 0.001).8  
 The incidence of in-hospital mortality was 9.3% in patients with primary PCI 
compared with 1.9% in patients treated with fibrinolysis (P = 0.03). This results in a risk 
ratio reduction of 80%. Stroke occurred in 3 patients (1 was hemorrhagic) that received 
fibrinolysis as compared with 0 patients that underwent primary PCI. The number of 
major bleeding events that justified transfusion was 4.6% in both the primary PCI and 
fibrinolytic groups.8 A summary of these findings can be found in Table II.  
 The median door to door time was 135 minutes for the primary PCI patients, 
compared with 128 minutes in patients transferred following fibrinolysis (P = 0.71). Door 
to door to balloon time in the primary PCI group was 182 minutes and the door to balloon 
time was 49 minutes from the time of arrival at PCMH. Median door to needle time in the 
fibrinolysis group was 30 minutes, with 51.4% being performed in less than 30 minutes. 
Rescue PCI has to be performed in 81 (37.5%) of the fibrinolytic patients, and coronary 
stents were placed in 75 (92.6%) of these patients.8 
Larson et al  
 In this prospective observational study,9 the authors compared the safety and 
efficacy of pharmaco-invasive PCI with immediate transfer for primary PCI in rural 
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patients with STEMI. In 2003, a regional system called the “Level 1 MI programme” was 
established to help with the management of STEMI patients transferred to the 
Minneapolis Heart Institute at Abbott Northwestern (MHI-ANW) Hospital in 
Minneapolis, Minnesota, a tertiary cardiovascular center, from community hospitals up to 
210 miles away. At the time of study, 11 referral hospitals were < 60 miles from MHI-
ANW (designated as Zone 1 hospitals) and 20 referral hospitals were 60-120 miles from 
MHI-ANW (designated as Zone 2 hospitals). Data was prospectively entered into a 
registry and clinical outcomes were extracted from the electronic medical record at 30 
days and 1 year. A propensity-score method was used to identify comparable patients 
treated with pharmaco-invasive reperfusion and those receiving primary PCI, in groups A 
and D. A nearest-neighbor 1:1 matching algorithm was used to match subjects on the 
basis of the logit of the propensity score.9  
 A standardized protocol with pre-printed standing orders was implemented at 
each hospital. Patients who presented to the PCI hospital (MHI-ANW) or were 
transferred from Zone 1 hospitals (< 60 miles), received primary PCI reperfusion therapy. 
Patients transferred from Zone 2 hospitals (> 60 miles) received half-dose fibrinolytic 
followed by emergent transfer for primary PCI (pharmaco-invasive PCI). The decision of 
type of fibrinolytic to administer was left up to individual hospital protocol, but 
tenecteplase (TNK) was the most frequently used (97% TNK, 3% reteplase). 
Contraindications to fibrinolysis included: active bleeding, significant closed head injury 
within 3 months, suspected aortic dissection, ischemic stroke within 3 months, known 
intracranial neoplasm or prior intracranial hemorrhage, and out of hospital cardiac arrest 
with prolonged CPR.9 
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 From April 2003 to December 2009, 2634 consecutive STEMI patients in the 
Level 1 MI database were enrolled. This study established five patients groups to help 
with comparison. Group A (n=600) – primary PCI patients who presented directly to the 
PCI hospital (MHI-ANW). Group B (n=1163) – primary PCI patients transferred from 
Zone 1 (< 60 miles) hospitals. Group C (n=32) – pharmaco-invasive PCI patients 
transferred from Zone 1 (< 60 miles) hospitals with anticipated delays due to weather. 
Group D (n=660) – pharmaco-invasive PCI patients transferred from Zone 2 (> 60 miles) 
hospitals. Group E (n=179) – primary PCI patients transferred from Zone 2 (> 60 miles).9  
 Pharmaco-invasive PCI with half-dose fibrinolysis was used in 692 (26.3%) 
patients including 660 from Zone 2 hospitals and 32 from Zone 1 hospitals with weather 
related transfer delays. For the most part groups were prognostically balanced. The 
pharmaco-invasive treated patients (Group C and D) were slightly older than Group A 
and B, while the patients from Zone 2 that were transferred for primary fibrinolysis 
(Group D) were older and had more risk factors.9 
 A pre-specified prospective comparison of patients treated with primary PCI that 
presented directly to the PCI hospital (Group A) with patients treated with pharmaco-
invasive PCI transferred from Zone 2 hospitals (Group D) showed no significant 
differences with respect to 30-day mortality (5.5 vs 5.6%; P=0.94), recurrent 
ischemia/AMI (2.5 vs 1.2%; P=0.088), stroke (1.3 vs 1.1%; P=0.66), or major bleeding 
(1.8 vs 1.5%; P=0.65). Also, when comparing the total number of patients that were 
treated with primary PCI from the PCI hospital and Zone 2 (Group A and B) with the 
total number of patients treated with pharmaco-invasive PCI (Group C and D) again 
showed no significant difference in 30-day mortality (5.6 vs 5.8%; P=0.87), stroke (0.9 
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vs 1.2%; P=0.48), recurrent ischemia/myocardial infarction (1.5 vs 1.3%; P=0.67) or 
major bleeding (1.4 vs 1.6%; P=0.76). After adjustment using the propensity-score 
method, these results were confirmed with similar outcomes when comparing Group A 
and D.9  A summary of these findings can be found in Table III.  
 Of the original group of patients that presented to Zone 2 hospitals, 21.3% did not 
receive fibrinolyic therapy and were transferred for primary PCI. Contraindications for 
fibrinolysis were the most common reason. These patients had higher 30-day mortality 
(10.6 vs 5.6%; P=0.17) compared with patients transferred from Zone 2 with pharmaco-
invasive PCI. These patients were higher risk as they were older, had more risk factors, 
and more likely to have had an out-of-hospital cardiac arrest (11.7 vs 7.0%; P=0.037).9 
 Median door to balloon times were 62 minutes for patients presenting directly to a 
PCI capable hospital (Group A), 92 minutes for primary PCI patients transferred from 
Zone 1 hospitals (Group B), and 122 minutes for pharmaco-invasive treated patients from 
Zone 2 hospitals (Group D). The median door to needle time was 29 minutes for patients 
receiving fibrinolytic therapy prior to transfer.9 
DISCUSSION 
 For all patients with STEMIs, both urban and rural, the recommended standard of 
treatment of primary PCI within 90 minutes of presenting to the hospital remains the gold 
standard for reperfusion therapy. However, of the thousands of patients that are 
diagnosed with STEMI every year in the United States, almost 75% of them present to 
hospitals lacking the staff and resources to preform primary PCI.11 Furthermore, with 
approximately 20% of the general population12 and more than 52% of the rural 
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population12 living more than 60 minutes from a primary PCI facility, achieving door to 
balloon times within 90 minutes remains a significant challenge.   
 Treatment of STEMI patients with fibrinolytic reperfusion therapy is a second-
line strategy due to its increase risk for bleeding and overall efficacy when compared to 
primary PCI.7 However, most would agree that the benefits of primary PCI decrease 
when there is a significant delay due to transfer.13-15 A recent study showed that patients 
who are transferred for primary PCI with delays to reperfusion greater than 90 minutes 
have significantly greater 30-day mortality.16 The study Beri et al8 found that rural 
STEMI patients who received fibrinolysis as an initial reperfusion strategy did not have 
overall worse outcomes like majoring bleeding, stroke, or death when compared to 
patients transferred directly for primary PCI. However, due to the overall very low 
quality, results from this article should be interpreted cautiously and a strong 
recommendation cannot be made on this article alone. Findings similar to Beri et al8 were 
reported in the DANAMI-2 trial,17 while the PRAGUE-218 and CAPTIM trials19 showed 
that thrombolysis might be an equally effective or better strategy than primary PCI in 
patients who could be reperfused within 2 to 3 hours of symptom onset. Other studies 
showed that as delays in transfers increased so did the benefit of fibrinolysis over primary 
PCI.13-15 Although these trials did not specifically study rural populations, transfer delay 
was the issue being addressed, which is the important problem at hand for rural patients. 
Multiple articles with similar findings help to strengthen the overall recommendation. In 
rural patients with STEMIs facing delays greater than 90 minutes, fibrinolytics appears to 
have no adverse effect in patients and may lead to better outcomes.  
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 An alternative strategy to these traditional methods of reperfusion is a treatment 
that combines the advantages of the availability of fibrinolysis with the effectiveness of 
primary PCI. The study Larson et al9 found that STEMI patients that presented to rural 
hospitals greater than 60 miles from PCI capable facilities routinely had delays in transfer 
times greater than 120 minutes. The results from this study for these patients indicate 
pharmaco-invasive PCI treatment being equally effective and safe with outcomes similar 
to patients presenting directly to a PCI-capable hospital.9 A recent meta-analysis20 
revealed that “routine early PCI, following fibrinolysis, in patients presenting to non-PCI 
hospitals, leads to significant reduction in re-infarction, recurrent ischemia, and the 
combined endpoint of death and re-infarction at 30 days with no significant increase in 
bleeding complications” compared with standard reperfusion therapy. The results found 
in the meta-analysis lead to a class 1a recommendation by the 2010 European Society of 
Cardiology and the European Association for Cardio-Thoracic Surgery guidelines on 
myocardial revascularization for transfer of all post-fibrinolysis STEMI patients to a PCI-
capable hospital for immediate rescue PCI if fibrinolysis is unsuccessful or coronary 
angiography within 3-24 hours and delayed PCI as needed.20 Despite these promising 
results, more research needs to be conducted on the exact pharmacologic regimen, 
dosing, and timing of PCI following fibrinolysis before any firm recommendations can be 
made.  
 While both studies8,9 demonstrated the safety and efficacy of alternative 
reperfusion strategies for rural STEMI patients, they are not without limitations. The Beri 
et al study8 was a retrospective observational study, automatically making it a low 
quality. The study was further downgraded to a very low due to the fact that the study 
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group was prognostically different then the control group and no statistical adjustment 
was done to make the groups equivalent. There may also been a selection bias due to the 
fact that there was a higher percentage of patients with heart failure and related 
cardiogenic shock in the primary PCI group compared to the fibrinolysis group.  
This may have led to sicker patients being designated for primary PCI rather than 
thrombolytics, resulting in delays in transfer and worse outcome. However, older patients 
with severe heart failure are more likely to have contraindications for fibrinolysis. This 
study was also limited to hospitals in the eastern part of North Carolina, and similar 
results may not be attained in other regions of the country.8  
 The Larson et al study9 was a registry investigational study and was therefore 
automatically a low quality to begin with. However, registry data does have the 
advantage of including a higher risk patient population not included in randomized 
trials,22 and recent research shows that it is difficult to enroll STEMI patients in a 
randomized control trial because of the lack of research support in rural hospitals.22,23 
Also results were obtained through an “organized STEMI system of care” that required 
significant physician and nurse training, and similar results may not be applicable to other 
areas that do not have similar systems.9  
CONCLUSION 
 When managing rural STEMI patients, direct transfer for primary PCI remains the 
strategy of choice for patients with contraindications to fibrinolysis or short transfer 
times. The benefit of primary PCI over fibrinolysis is reduced when there is a significant 
delay related to transfer,13-15 making on-site fibrinolytic therapy a more practical option 
for reperfusion as transfer times increase. The relatively new method of pharmaco-
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invasive therapy may be a safe and effective reperfusion strategy for rural STEMI 
patients when delays are expected due to long-distance travel. Further studies reinforcing 
the safety and efficacy, as well as establishing a standardized protocol will help to 
strengthen this recommendation. 
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Table I. Characteristics of Reviewed Studies 
 
 
 
 
 
 
 
 
 
 
 
Quality Assessment  
Importance  Downgrade Criteria 
Quality No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Mortality   
 
2 
 
 Observational   Serious limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely Very Low Critical 
Re-infarction    
1 Observational No serious limitations 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely Very Low Critical 
Stroke   
2  Observational Serious limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely Very Low Critical  
Major Bleeding    
2 Observational Serious limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely Very Low Critical  
a Study group is prognostically different then control group in Beri et al,8 with no statistical adjustment done  
bOnly one study evaluated this outcome 
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Table II. Summary of Findings Beri et al8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Number of Patients Outcomes 
Group pPCI (total) Mortality (%) Effect Stroke  Major Bleed  
Fibrinolytic 216 4 (1.9) Relative Risk Reduction: 0.80 3 (1.4) 10 (4.6) 
Primary PCI 43 4 (9.3) Number Needed to Treat: 14 0 (0.0) 2 (4.7) 
pPCI, primary percutaneous coronary intervention. 
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Table III. Summary of Findings Larson et al9 
 
 
Study Number of Patients Outcomes 
Larson et al9 Treatment (total) Mortality Re-infarction Stroke  Major Bleed  Relative Risk  
          Group A         (pPCI, PCI hospital) 600 33 (5.5) 15 (2.5) 8 (1.3) 11 (1.8) 
          Group B         (pPCI, Zone 1) 1163 66 (5.7) 12 (1.0) 7 (0.6) 14 (1.2) 
          Total pPCI      (A + B) 1763 99 (5.6) 27 (1.5) 15 (0.9) 25 (1.4) 
          Group C         (PI, Zone 1) 32 3 (9.6) 1 (3.1) 1 (3.1) 1 (3.1) 
          Group D         (PI, Zone 2) 660 37 (5.6) 8 (1.2) 7 (1.1) 10 (1.5) 
          Total PI          (C +D) 692 40 (5.8) 9 (1.3) 8 (1.2) 11 (1.6) 
          Group E         (pPCI, Zone 2) 179 19 (10.6) 2 (1.1) 2 (1.1) 3 (1.7) 
pPCI,  primary percutaneous coronary intervention; PCI, percutaneous coronary intervention; PI, pharmaco-invasive. 
Mortality Relative Risk when comparing Group A to Group D is 1.02 
 
